FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 229 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Can Artificial Intelligence Help See Cancer in New, and Better, Ways? March 22, 2022 Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... April 8, 2022 Rapid Genetic Test Could Help Guide Brain Cancer Surgery May 8, 2025 Load more HOT NEWS Texting May Help Reduce Disparities in Colorectal Cancer Screening Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... Diving into our role in 50 top cancer drugs
